Olmesartan Macleods (Olmesartan Medoxomil)

Olmesartan medoxil selectively blocks the angiotensin II type‑1 (AT1) receptor, preventing angiotensin II‑induced vasoconstriction and aldosterone release. This leads to relaxation of blood vessels, reduced peripheral resistance and ultimately lower arterial blood pressure.

The dosage of Olmesartan Macleods is individualized by the prescribing healthcare professional based on the patient’s blood pressure, response to therapy and any co‑existing medical conditions. The prescriber determines the appropriate strength and dosing schedule.

Olmesartan Macleods is contraindicated in the second and third trimesters of pregnancy because it can cause fetal toxicity. Limited data are available for breastfeeding; therefore, it should only be used if the potential benefit justifies the possible risk to the infant.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmesartan, as an ARB, provides blood‑pressure reduction comparable to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers or diuretics, it works through the renin‑angiotensin system and is often chosen when those agents are insufficient or not tolerated.

Store Olmesartan Macleods tablets at temperatures below 25 °C in their original container, protected from moisture and direct light. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

Olmesartan Macleods is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events include angio‑edema, severe hypotension, acute kidney injury and hyperkalaemia. Patients should be monitored for signs of swelling, sudden drops in blood pressure, changes in kidney function or elevated potassium levels, especially when used with other renin‑angiotensin drugs.

Olmesartan Macleods should be avoided in patients with known hypersensitivity to olmesartan or any tablet excipients, in pregnant women during the second and third trimesters, and in individuals receiving concurrent therapy with another ARB or ACE inhibitor unless specifically directed by a physician.